Sources New England Journal of Medicine: TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial New England Journal of Medicine: Once-Weekly Semaglutide in Adults with Overweight or Obesity Eli Lilly: News Release: Lillys phase 2 retatrutide results published in The New England Journal of Medicine Clinical Trials Arena: Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins Eli Lilly: News Release: Lillys tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Medical Disclaimer This article, Retatrutide Weight Loss Results: Retatutride vs Tirzepatide vs Semaglutide , is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment
Adjusting the dosage based on individual responses can help maximize these benefits
Evidence base reflects FertilitySmart's editorial summary of the trial literature cited in this article: A indicates multiple RCTs supported by meta-analysis
Some estimates put the global GLP-1 market closing in on half a trillion dollars by 2032
In humans, GLP-1Rs are found in a variety of tissues, including pancreatic islets, the lungs, the kidneys, the gastrointestinal tract, the central nervous system, the vagus nerve, endothelial cells and smooth muscle cells, as well as in atrial and ventricular cardiomyocytes
